Lastacaft
(Alcaftadine)ApprovedSmall molecule
AbbVieLastacaft is one of 30 small molecule programs targeting Eye Allergy. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
29
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
149 competitors in Allergy
#DrugCompanyPhaseTrials
1Flovent
GSKPhase 3
Clarinex
OOrganon and Co
Phase 3
Xolair
RochePhase 2
Lastacaft
AbbVieApproved
REGN5713
RegeneronPhase 3
REGN5715
RegeneronPhase 3
Ligelizumab
NovartisPhase 3
Allergy Immunotherapy (AIT)
AALK-Abelló A/S
Phase 3
Antihistamine
Arrowhead PharmaceuticalsPhase 2
AR101
AAimmune Therapeutics, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jul 28, 2010
LASTACAFT
NDA NDA022134
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alcaftadine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]